"The Champagne should probably be kept on ice, at least until the two presidents put pen to paper," said state-owned media China Daily.Traderead more
U.S. stock index futures turned lower after China said it needed to have further discussions before it would sign off on the so-called phase one trade deal President Trump...US Marketsread more
Analysts say the partial U.S.-China trade deal doesn't touch on thorny issues plaguing both sides, and warn talks could break down again.World Economyread more
Economists polled by Reuters had expected Chinese exports denominated in the U.S. dollar to fall by 3% and imports to decline by 5.2% in September, compared to a year ago.China Economyread more
Economists Abhijit Banerjee, Esther Duflo and Michael Kremer won the 2019 Nobel Economics Prize for their work in fighting global poverty, the Royal Swedish Academy of...World Newsread more
Boeing's board removed CEO Dennis Muilenburg as chairman amid the fall out of two 737 Max crashes that killed 346 people.Aerospace & Defenseread more
The U.K. and EU are gearing up for what could be the busiest week in British politics since June 2016.Europe Politicsread more
The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
"It seems like what the two leaders have done is try to set some of the thorny political issues to the side," said Dhruva Jaishankar, director of the U.S. Initiative at the...Asia Politicsread more
Beijing will be opening up its financial industry to foreign ownership from January, namely in the areas of futures, mutual funds and securities.China Economyread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
Strategist David Rosenberg named demographics the single most important factor for financial analysts and investors to monitor over the next decade.
"If it's all about 'follow the money,'" wrote Gluskin Sheff's Rosenberg, "then it is 'follow the boomers.'"
"Nothing is more important than this if you are looking at what will fundamentally influence the financial markets for the next decade-plus," he added.
The first of the baby boomers turned 70 this year, with another 1.5 million reaching that milestone each year for the next 15 years.
Crediting these demographic aging trends with the continued, "lower for longer theme" — lower growth, lower inflation and lower bond yields — Rosenberg noted that the markets' biggest surprise this year after the election of President Donald Trump was not the stock market.
Source: David Rosenberg, Gluskin Sheff
"It has clearly been the bond market, as the yield on the 10-year Treasury note, instead of breaking to or through the 3% threshold, never did come close and now resides south of 2.3%," added Rosenberg.
"Aggregate growth in incomes and spending will be decelerating, and that will be posing additional deflationary pressures in the economy, and this in and of itself will ensure bond yields remain extremely low."
Rosenberg's research also found that as a cohort, boomers spend more on "experiences" like leisure, hospitality, recreation, entertainment and travel.
"As a share of income, those 65 and older actually dole out more on these services than the folks in the age groups behind them."
According to the latest Transamerica Retirement Survey, some 65 percent of baby boomers cited travel most often as their top dream for retirement, above spending more time with family or pursuing hobbies.
But to be sure, travel and hospitality aren't the only industries Rosenberg suggests investors eye as the U.S. population ages.
Biotech and medicine are positioned for continued growth as boomers consume more and more health care.
Spending on health care accounts for 16.6 percent of U.S. GDP, 5 percentage points more than Switzerland, the next closest country.
The iShares Nasdaq Biotechnology ETF (IBB) is up 23 percent year to date, hinting at strong growth in large pharmaceutical and other biotech companies in the coming years.